Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist clinically approved for type 2 diabetes and obesity management, has demonstrated pleiotropic effects in preclinical NAFLD models. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.